Amdocs (NASDAQ:DOX – Get Free Report) had its target price dropped by Stifel Nicolaus from $71.00 to $46.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the technology company’s stock. Stifel Nicolaus‘s price target suggests a potential downside of 26.32% from the company’s previous close.
DOX has been the subject of a number of other reports. Weiss Ratings upgraded shares of Amdocs from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, October 23rd. Wall Street Zen upgraded Amdocs from a “hold” rating to a “buy” rating in a research note on Saturday, August 29th. Finally, Oppenheimer downgraded Amdocs from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $78.33.
Check Out Our Latest Report on DOX
Amdocs Stock Performance
Shares of DOX stock opened at $62.43 on Wednesday. The company has a 50 day moving average price of $60.65 and a 200-day moving average price of $62.58. Amdocs has a 52 week low of $49.74 and a 52 week high of $85.63. The firm has a market capitalization of $6.74 billion, a PE ratio of 9.88, a P/E/G ratio of 1.01 and a beta of 0.42. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 0.23.
Amdocs (NASDAQ:DOX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The technology company reported $1.98 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.98. Amdocs had a net margin of 9.75% and a return on equity of 20.28%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the prior year, the firm earned $1.83 earnings per share. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, equities research analysts expect that Amdocs will post 6.57 earnings per share for the current year.
Institutional Trading of Amdocs
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ethic Inc. boosted its stake in shares of Amdocs by 117.4% during the 3rd quarter. Ethic Inc. now owns 22,384 shares of the technology company’s stock worth $1,280,000 after acquiring an additional 12,090 shares during the last quarter. Alps Advisors Inc. grew its position in shares of Amdocs by 20.3% during the 3rd quarter. Alps Advisors Inc. now owns 264,909 shares of the technology company’s stock valued at $15,147,000 after acquiring an additional 44,786 shares during the period. Commonwealth Equity Services LLC grew its position in shares of Amdocs by 23.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,515 shares of the technology company’s stock valued at $944,000 after acquiring an additional 3,187 shares during the period. Covestor Ltd increased its stake in shares of Amdocs by 11.8% in the 3rd quarter. Covestor Ltd now owns 2,461 shares of the technology company’s stock worth $141,000 after purchasing an additional 259 shares in the last quarter. Finally, Pzena Investment Management LLC increased its stake in shares of Amdocs by 3.4% in the 3rd quarter. Pzena Investment Management LLC now owns 14,454,911 shares of the technology company’s stock worth $826,532,000 after purchasing an additional 469,581 shares in the last quarter. 92.02% of the stock is owned by hedge funds and other institutional investors.
More Amdocs News
Here are the key news stories impacting Amdocs this week:
- Positive Sentiment: Amdocs expanded its collaboration with AT&T on AI-enabled operations modernization, offering a potential opportunity to deepen business with a major telecom customer. AT&T and Amdocs Expand Collaboration
- Positive Sentiment: The company declared a quarterly dividend of $0.569 per share, equivalent to an annualized $2.28. Amdocs dividend announcement
- Neutral Sentiment: Amdocs agreed to acquire insurance technology company EIS for $340 million, giving it a potential entry into a new market, though the deal adds execution and integration considerations. Amdocs acquires EIS
- Neutral Sentiment: Fiscal fourth-quarter adjusted EPS of $1.98 and revenue of $1.19 billion matched estimates; revenue grew 3.8% year over year. The in-line results offered little offset to concerns about the forward outlook. Amdocs Q4 earnings flash
- Negative Sentiment: A dispute with T-Mobile is clouding Amdocs’ outlook. The company cut its fiscal 2027 revenue guidance, and the CEO declined to detail the company’s revenue exposure to T-Mobile, leaving investors uncertain about the potential scale of the impact. Amdocs CEO declines to detail T-Mobile exposure
- Negative Sentiment: Oppenheimer downgraded Amdocs to Perform, adding to the cautious tone around the lowered outlook and customer dispute. Oppenheimer downgrades Amdocs
Amdocs Company Profile
Amdocs Ltd. (NASDAQ: DOX) is a global provider of software and technology services for communications, media and entertainment companies. Its solutions help service providers manage customer relationships, billing, subscriptions, product offerings and digital experiences across consumer and enterprise markets.
The company’s portfolio includes business support systems and operational support systems, cloud-based software, artificial intelligence and automation tools, network and service management platforms, and solutions for media distribution and monetization.
Read More
- Five stocks we like better than Amdocs
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.
